Literature DB >> 23531391

Drug-resistant tuberculosis: time for visionary political leadership.

Ibrahim Abubakar1, Matteo Zignol, Dennis Falzon, Mario Raviglione, Lucica Ditiu, Susan Masham, Ifedayo Adetifa, Nathan Ford, Helen Cox, Stephen D Lawn, Ben J Marais, Timothy D McHugh, Peter Mwaba, Matthew Bates, Marc Lipman, Lynn Zijenah, Simon Logan, Ruth McNerney, Adam Zumla, Krishna Sarda, Payam Nahid, Michael Hoelscher, Michel Pletschette, Ziad A Memish, Peter Kim, Richard Hafner, Stewart Cole, Giovanni Battista Migliori, Markus Maeurer, Marco Schito, Alimuddin Zumla.   

Abstract

Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium tuberculosis were susceptible to first-line tuberculosis drugs, and drug resistance was not a major issue. However, in 2013, tuberculosis remains a major public health concern worldwide, with prevalence of multidrug-resistant (MDR) tuberculosis rising. WHO estimates roughly 630 000 cases of MDR tuberculosis worldwide, with great variation in the frequency of MDR tuberculosis between countries. In the past 8 years, extensively drug-resistant (XDR) tuberculosis has emerged, and has been reported in 84 countries, heralding the possibility of virtually untreatable tuberculosis. Increased population movement, the continuing HIV pandemic, and the rise in MDR tuberculosis pose formidable challenges to the global control of tuberculosis. We provide an overview of the global burden of drug-resistant disease; discuss the social, health service, management, and control issues that fuel and sustain the epidemic; and suggest specific recommendations for important next steps. Visionary political leadership is needed to curb the rise of MDR and XDR tuberculosis worldwide, through sustained funding and the implementation of global and regional action plans.
Copyright © 2013 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23531391     DOI: 10.1016/S1473-3099(13)70030-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  81 in total

1.  The challenge of sustaining effectiveness over time: the case of the global network to stop tuberculosis.

Authors:  Kathryn Quissell; Gill Walt
Journal:  Health Policy Plan       Date:  2015-08-17       Impact factor: 3.344

2.  Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.

Authors:  Michael B Harbut; Catherine Vilchèze; Xiaozhou Luo; Mary E Hensler; Hui Guo; Baiyuan Yang; Arnab K Chatterjee; Victor Nizet; William R Jacobs; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 3.  TB and HIV in the Central African region: current knowledge and knowledge gaps.

Authors:  S Janssen; M A M Huson; S Bélard; S Stolp; N Kapata; M Bates; M van Vugt; M P Grobusch
Journal:  Infection       Date:  2013-12-06       Impact factor: 3.553

4.  Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data.

Authors:  Jonathan L Zelner; Megan B Murray; Mercedes C Becerra; Jerome Galea; Leonid Lecca; Roger Calderon; Rosa Yataco; Carmen Contreras; Zibiao Zhang; Justin Manjourides; Bryan T Grenfell; Ted Cohen
Journal:  J Infect Dis       Date:  2015-07-14       Impact factor: 5.226

5.  In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Yu Pang; Zhaojing Zong; Fengmin Huo; Wei Jing; Yifeng Ma; Lingling Dong; Yunxu Li; Liping Zhao; Yuhong Fu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

6.  The political and ethical challenge of multi-drug resistant tuberculosis.

Authors:  Chris Degeling; Christopher Mayes; Wendy Lipworth; Ian Kerridge; Ross Upshur
Journal:  J Bioeth Inq       Date:  2015-01-29       Impact factor: 1.352

7.  A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.

Authors:  Alexander L Perryman; Weixuan Yu; Xin Wang; Sean Ekins; Stefano Forli; Shao-Gang Li; Joel S Freundlich; Peter J Tonge; Arthur J Olson
Journal:  J Chem Inf Model       Date:  2015-02-17       Impact factor: 4.956

Review 8.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

9.  From Exceptional to Liminal Subjects: Reconciling Tensions in the Politics of Tuberculosis and Migration.

Authors:  Jed Horner
Journal:  J Bioeth Inq       Date:  2016-01-12       Impact factor: 1.352

10.  Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis.

Authors:  Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew Magee; Henry M Blumberg; Russell R Kempker
Journal:  Clin Infect Dis       Date:  2014-08-04       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.